Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 4376962)

Published in Adv Ther on March 18, 2015


François Laliberté1, Michel Cloutier, Concetta Crivera, Winnie W Nelson, William H Olson, Jeffrey Schein, Julie Vanderpoel, Guillaume Germain, Patrick Lefebvre

Author Affiliations

1: Groupe d'analyse, Ltée, 1000 De La Gauchetière Ouest, Bureau 1200, Montréal, QC, H3B 4W5, Canada, francois.laliberte@analysisgroup.com.

Associated clinical trials:

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate | NCT00262600

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation | NCT00403767

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE) | NCT00412984

Articles cited by this

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol (2001) 7.46

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Estimating medical costs from incomplete follow-up data. Biometrics (1997) 3.25

Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25

Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 2.61

Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation (2014) 2.19

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol (2012) 1.79

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke (2013) 1.37

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology (2012) 1.05

Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin (2005) 1.04

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig (2014) 0.93

Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One (2013) 0.93

New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87

New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther (2012) 0.86

Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs. Adv Ther (2014) 0.85

The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract (2013) 0.85

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82

Inefficiencies in osteoarthritis and chronic low back pain management. Am J Manag Care (2013) 0.82

Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther (2014) 0.79

Oral and parenteral anticoagulants: new kids on the block. J Postgrad Med (2013) 0.78

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin (2014) 0.78

Lessons from the leucovorin shortages between 2009 and 2012 in a medicare advantage population: where do we go from here? Am Health Drug Benefits (2014) 0.77

Novel oral anticoagulants for atrial fibrillation. Curr Atheroscler Rep (2013) 0.77

Articles by these authors

Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med Care (2005) 2.33

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10

Priorities among effective clinical preventive services: methods. Am J Prev Med (2006) 2.01

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. J Med Econ (2014) 2.00

Epidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort study. J Infect (2010) 1.83

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension (2012) 1.65

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology (2012) 1.62

Monitoring of drugs with a narrow therapeutic range in ambulatory care. Am J Manag Care (2006) 1.60

Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest (2004) 1.53

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion (2009) 1.53

Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother (2003) 1.49

Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm (2006) 1.46

Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause (2015) 1.45

Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother (2006) 1.42

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin (2006) 1.41

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin (2014) 1.36

Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord (2006) 1.31

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm (2009) 1.25

Interrupted time series analysis in clinical research. Ann Pharmacother (2003) 1.20

Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care (2007) 1.14

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol (2009) 1.10

A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med (2008) 1.09

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw (2005) 1.06

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin (2008) 1.04

Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J (2004) 1.04

Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am J Manag Care (2004) 1.03

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03

Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther (2012) 0.98

Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv (2010) 0.98

Use of warfarin in long-term care: a systematic review. BMC Geriatr (2012) 0.98

Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol (2013) 0.96

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin (2008) 0.96

Burden of comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis (2012) 0.96

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol (2012) 0.95

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol (2008) 0.95

Draft Genome Sequence of Arcobacter cibarius Strain LMG21996T, Isolated from Broiler Carcasses. Genome Announc (2014) 0.95

Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med (2005) 0.95

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94

System-related events and analgesic gaps during postoperative pain management with the fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia. Anesth Analg (2007) 0.94

Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. Pharmacoeconomics (2008) 0.93

A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther (2002) 0.91

A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry (2005) 0.91

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr Med Res Opin (2009) 0.91

Anaemia and the risk of injurious falls in a community-dwelling elderly population. Drugs Aging (2008) 0.90

Ease of care with patient controlled analgesia systems: questionnaire development and validation. J Adv Nurs (2007) 0.90

Baseline laboratory monitoring of cardiovascular medications in elderly health maintenance organization enrollees. J Am Geriatr Soc (2005) 0.90

Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt) (2012) 0.89

Development and validation of a new instrument to evaluate the ease of use of patient-controlled analgesic modalities for postoperative patients. J Med Econ (2010) 0.89

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry (2013) 0.88

Patient-controlled analgesia-related medication errors in the postoperative period: causes and prevention. Drug Saf (2009) 0.88

The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache (2007) 0.87

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86

Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation. Clin Ther (2012) 0.85

Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother (2007) 0.85

Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. J Med Econ (2011) 0.84

The economic burden of acute coronary syndromes for employees and their dependents: medical and productivity costs. J Occup Environ Med (2013) 0.84

Systematic literature review of the costs of pregnancy in the US. Pharmacoeconomics (2013) 0.84

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin (2014) 0.84

Dyspepsia and disease burden among patients with atrial fibrillation. Crit Pathw Cardiol (2012) 0.84

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin (2013) 0.84

Outcomes associated with comorbid atrial fibrillation and heart failure in Medicare beneficiaries with acute coronary syndrome. BMC Health Serv Res (2014) 0.83

Association between consistent omalizumab treatment and asthma control. J Allergy Clin Immunol Pract (2012) 0.83

Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. J Med Econ (2009) 0.83

Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci (2013) 0.83

Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. J Med Econ (2010) 0.83

Physician-patient interaction for smoking cessation medications: a dance of mutual accommodation? J Am Board Fam Med (2006) 0.83

Clinical and economic outcomes among hospitalized patients with acute coronary syndrome: an analysis of a national representative Medicare population. Clinicoecon Outcomes Res (2013) 0.83

Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care (2005) 0.82

Indirect costs associated with nonadherence to treatment for bipolar disorder. J Occup Environ Med (2010) 0.82

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ (2013) 0.82

Patient satisfaction with warfarin- and non-warfarin-containing thromboprophylaxis regimens for atrial fibrillation. J Investig Med (2013) 0.81

Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care (2014) 0.81

Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. Hum Vaccin Immunother (2014) 0.81

Persistence of warfarin therapy for residents in long-term care who have atrial fibrillation. Clin Ther (2013) 0.81

Draft genome sequences of two arcobacter strains isolated from human feces. Genome Announc (2014) 0.81

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. J Med Econ (2011) 0.81

Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. Ann Pharmacother (2005) 0.80

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. Oncologist (2005) 0.80

Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia (2010) 0.80

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry (2011) 0.80

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm (2007) 0.80

Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer. J Manag Care Spec Pharm (2014) 0.80

Burden of schizophrenia on selected comorbidity costs. Expert Rev Pharmacoecon Outcomes Res (2014) 0.80

A method for imputing the impact of health problems on at-work performance and productivity from available health data. J Occup Environ Med (2009) 0.79

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Drugs Aging (2006) 0.79

Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav (2010) 0.79

Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population. J Med Econ (2010) 0.79